EUVIMEDEUVIMED entdecken
Crossref

Neurosurgical software device safety in the US: analysis of 2017–2025 FDA Recall and Adverse Event Data

Kashif Qureshi, Jose Anzueto, Tarishi Parmar, George Sun, Anudeep Yekula, Rahul H Jayaram, Viveka Chinnasamy, James Alvin, Sebastian Saenz, Carlos Goulart, Kai Yu, Catherine Jayakumar und 1 weitere

Neurosurgical Focus · 01.11.2026 · 61 (5) · E12

DOI: 10.3171/2026.8.focus26413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, erschienen am 01.11.2026. Verfasst von Kashif Qureshi und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Yale University, New Haven, Connecticut. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Software, Medical Device Recalls, Neurosurgical Procedures. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Neurosurgeons rely on multiple software applications for surgical planning, intraoperative navigation, and neurophysiological monitoring. Combined with the proliferation of AI-based clinical adjuncts, software as a medical device (SaMD) represents an evolving frontier with profound implications for patient safety. The aim of this study was to systematically analyze all software-related neurological medical device recalls initiated in the US from 2017 to 2025 and to assess the implications of recalls and adverse events for software devices currently in use, as well as the risks posed by emerging software platforms. METHODS Recall and adverse event information related to neurological SaMDs (2017–2025) was extracted from the FDA recall, MAUDE, AccessGUDID, and openFDA databases. Product codes were identified using the FDA Product Classification database. Associated adverse event data were extracted using a custom Python script with the openFDA application programming interface. RESULTS There were 20 unique software-associated neurological device recalls identified across 7 medical device companies and 4 distinct device categories, namely surgical navigation (55%), neurophysiological monitoring devices (25%), surgical planning (15%), and stereotactic devices (5%). More than half of the neurological devices that were recalled had FDA class I severity. Recalls categorized as class I displayed a significant upward trend in annual frequency from 2017 to 2024 (p = 0.027). The median recall times were shorter for class I versus class II recalls (4 vs 10 years, IQR 2–7 vs 6–11 years; Mann-Whitney U = 28, p = 0.182). There were 16,333 adverse event notifications, with 93.4% related to malfunction and 5.9% related to injury. Two surgical navigation devices alone were responsible for 88.8% of all documented adverse events. There was a significantly higher rate of severe adverse harm reported among class II than class I recalls (14.6% vs 3.6%, p < 0.001). More than 10,000 adverse events were reported after formal recall notification for two medical devices. System instability (55.0%) and software defects (43.5%) comprised 98.5% of adverse event notifications. CONCLUSIONS Device recalls and adverse events associated with neurological SaMDs trended toward greater severity of harm, were concentrated in a few high-throughput platforms, and generated a significant volume of adverse events that persisted even after the recall procedure took effect. The observed discordance between recall class and reported patient harm, as well as the prevalence of runtime instability as the most common software failure mode, represent potential areas of improvement for current regulatory frameworks. Adaptation by regulatory bodies and vigilance by providers is critical, particularly for identifying SaMD-related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationSoftwareMedical Device RecallsNeurosurgical ProceduresEquipment SafetyHumansUnited StatesDatabases, Factual

Stichwörter der Autor:innen

intraoperative neurophysiological monitoringmedical device recallmedical device regulationneuronavigationpostmarket surveillancesoftware as a medical device

Autor:innen und Institutionen

  • 1Department of Neurosurgery, Yale University, New Haven, Connecticut.
  • 2Division of Shoulder and Elbow Surgery, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania.
  • 3Department of Neurosurgery, University of Minnesota, Minneapolis.
  • 4Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota.
  • 5Department of Economics, Duke University, Durham.
  • 6Department of Mathematics, Duke University, Durham, North Carolina.

Zitieren

APA

Qureshi, K., Anzueto, J., Parmar, T., Sun, G., Yekula, A., Jayaram, R. H., Chinnasamy, V., Alvin, J., Saenz, S., Goulart, C., Yu, K., Jayakumar, C., & Gupta, M. (2026). Neurosurgical software device safety in the US: analysis of 2017–2025 FDA Recall and Adverse Event Data. Neurosurgical Focus, 61(5), E12. https://doi.org/10.3171/2026.8.focus26413

Vancouver

Qureshi K, Anzueto J, Parmar T, Sun G, Yekula A, Jayaram RH, et al. Neurosurgical software device safety in the US: analysis of 2017–2025 FDA Recall and Adverse Event Data. Neurosurgical Focus. 2026;61(5):E12. doi:10.3171/2026.8.focus26413

BibTeX
@article{Qureshi2026,
  author = {Qureshi, Kashif and Anzueto, Jose and Parmar, Tarishi and Sun, George and Yekula, Anudeep and Jayaram, Rahul H and Chinnasamy, Viveka and Alvin, James and Saenz, Sebastian and Goulart, Carlos and Yu, Kai and Jayakumar, Catherine and Gupta, Mihir},
  title = {Neurosurgical software device safety in the US: analysis of 2017–2025 FDA Recall and Adverse Event Data},
  journal = {Neurosurgical Focus},
  year = {2026},
  volume = {61},
  number = {5},
  pages = {E12},
  doi = {10.3171/2026.8.focus26413}
}
Kostenlos starten →